TL;DR
This study introduces CuS-BSA nanoparticles, a novel material synthesized using copper sulfide and bovine serum albumin, for photothermal therapy of hepatocellular carcinoma (HCC). These nanoparticles effectively generate heat under near-infrared light, leading to tumor cell death and inhibition of tumor growth in mice, with promising biosafety profiles.
What Problem Does This Paper Address?
Hepatocellular carcinoma (HCC) is a significant global health challenge, and while surgery offers a cure for early-stage patients, many are ineligible due to disease progression or other health issues. Conventional treatments like chemotherapy and radiotherapy often suffer from severe side effects due to their non-specific targeting of healthy tissues. Photothermal therapy (PTT) has emerged as a promising alternative, utilizing near-infrared (NIR) light to heat and destroy cancer cells. However, the development of effective, biocompatible, and stable photothermal agents remains a key challenge. This paper addresses the need for such agents by developing and evaluating CuS-BSA nanoparticles, aiming to improve PTT efficacy and safety for HCC treatment.
Methods
The researchers synthesized sheet-like CuS-BSA nanoparticles with an average size of 30 nm using a facile one-pot strategy, employing bovine serum albumin (BSA) as a biological modifier. They characterized these nanoparticles using transmission electron microscopy (TEM) and dynamic light scattering (DLS) for size and morphology, and UV-Vis spectrophotometry to assess their light absorption properties, particularly in the NIR region.
To evaluate biosafety, they conducted in vivo toxicity studies on Kunming mice. Different doses of CuS-BSA nanoparticles were administered via tail vein injection, and the mice were monitored for 14 days. Organ damage (liver, kidney, spleen) was assessed through histopathological examination, and organ indices (thymus and spleen) were calculated.
For photothermal therapy efficacy, H22 hepatoma-bearing mouse models were established. CuS-BSA nanoparticles were administered either via tail vein injection or intratumoral injection at a dose of 600 µg/kg. These mice were then exposed to a 980 nm NIR laser (2.0 W/cm²) for 10 minutes weekly for three weeks. Tumor volume and body weight were monitored throughout the treatment. Post-treatment, tumor tissues were analyzed for necrosis and apoptosis using hematoxylin and eosin (H&E) staining and immunohistochemistry to detect the expression of cleaved caspase-3 and cleaved caspase-9, key markers of apoptosis.
Datasets
Not discussed in the paper. The study utilized in vivo experiments with H22 hepatoma-bearing mice and control groups.
Key Insights and Ideas
- BSA as a Biocompatible Modifier: The use of bovine serum albumin (BSA) as a modifier for copper sulfide nanoparticles (CuS NPs) proved crucial. BSA not only improved the dispersibility and stability of the CuS NPs but also enhanced their biocompatibility, addressing potential toxicity concerns associated with bare CuS NPs.
- NIR Absorption and Photothermal Conversion: CuS-BSA NPs exhibited a strong absorption peak in the near-infrared (NIR) region (980 nm), which is ideal for PTT as NIR light can penetrate tissues more effectively than visible light. This absorption translates into efficient conversion of light energy into heat.
- Concentration and Power Dependence: The photothermal effect of CuS-BSA NPs was found to be dependent on both the concentration of the nanoparticles and the power density of the NIR laser. This allows for tunable therapeutic outcomes.
- Effective Tumor Ablation: The study demonstrated that CuS-BSA NPs, when combined with NIR irradiation, could significantly inhibit tumor growth in H22 hepatoma-bearing mice. This effect was observed with both tail vein and intratumoral injections, suggesting good accumulation and efficacy.
- Induction of Apoptosis: Beyond direct thermal ablation, the CuS-BSA NP-mediated PTT also induced apoptosis in tumor cells, as evidenced by the upregulation of cleaved caspase-3 and cleaved caspase-9. This dual mechanism (necrosis and apoptosis) likely contributes to the overall therapeutic effectiveness.
- Favorable Biosafety Profile: The in vivo toxicity studies indicated that CuS-BSA NPs exhibited low toxicity at relevant therapeutic doses, with no significant pathological changes observed in major organs like the liver, kidney, and spleen.
Key Results
- CuS-BSA NPs were successfully synthesized with a particle size of approximately 30 nm and showed good dispersibility in various biological media (ultrapure water, PBS, DMEM).
- The nanoparticles exhibited a strong absorption peak at 980 nm, crucial for NIR-based PTT.
- In vivo toxicity studies showed no significant organ damage at doses up to 7,200 µg/kg, suggesting good biosafety.
- In H22 hepatoma-bearing mice, CuS-BSA NPs (600 µg/kg) combined with 980 nm NIR irradiation resulted in significant tumor growth inhibition (48.8% and 41.5% for intratumoral and tail vein injection, respectively).
- Histopathological analysis of tumors treated with CuS-BSA NPs and NIR irradiation revealed large areas of necrosis and significantly increased expression of cleaved caspase-3 and cleaved caspase-9, indicating apoptosis.
Limitations and Future Work
The authors acknowledge that the study's limitation lies in using only one dose and one power density for the tumor photothermal ablation experiment. They suggest that future research should explore a wider range of doses and power densities to further optimize the therapeutic parameters. Additionally, while the study provides promising results for HCC, further investigation into the long-term efficacy, potential side effects, and translation to clinical applications would be beneficial. The exploration of other cancer types and the development of more targeted delivery strategies could also be valuable future directions.
Summary updated